NCT04631575Unknown1 期
A Single Dose, Open-label, Parallel Controlled Pharmacokinetic Study of SHR6390 in Participants With Mild to Moderate Liver Impairment and Healthy Participants
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 24
- 主要终点
- Cmax
研究概览
简要总结
The purpose of this study is to investigate SHR6390 in participants with different levels of liver function
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants with mild to moderate liver impairment must meet all of the following criteria to enter the study:
- •The informed consent is signed before the trial, and the content, process and possible adverse reactions are fully understood; Be able to complete the study according to the requirements of the test scheme;
- •Both male and female, subjects aged 18 to 65 years (including both ends) on the date of signing informed consent;
- •The body weight of male subjects is ≥50 kg, while female subjects is ≥45 kg. Body mass index (BMI) is in the range of 18.5 kg/m2-30 kg/m2;
- •Chronic stable primary liver disease is necessary for patients with liver impairment, then patients with Grade-A/mild liver impairment (Child-Pugh score: 5-6) and Grade-B/moderate liver impairment (Child-Pugh score: 7-6) are assessed according to Child-Pugh classification;
- •Provide documentary evidence of confirmed liver impairment;
- •Patients who have stable medication regimen for liver impairment, complications and other concomitant diseases within at least 28 days before taking the experimental drug, and the medication does not need to be adjusted (including drug type, dosage or frequency) during the clinical trials; or those who do not use the drug;
- •The function of vital organs meets the following criteria: Absolute neutrophil count (ANC) ≥ 1.0 × 109 / L (1000 / mm3); Platelet ≥ 75.0 × 109 / L (75000 / mm3); Hemoglobin (Hgb) ≥ 9.0 g / dL (90g / L); ALT and AST ≤ 5ULN; Creatinine clearance rate (CLcr) ≥ 60 mL / min; The corrected QTc interval (QTcF) ≤ 450 msec (male), ≤ 470 msec (female);
- •In addition to liver impairment and complications, the investigator judged good condition according to the history inquiry, vital signs, physical examination, routine laboratory examination, 12-lead ECG, EEG, etc., and there was no other clinically significant abnormality;
- •No family planning during the trial and within 6 months after the last administration of the trial drug, and voluntarily take effective contraceptive measures; Serum pregnancy test must be negative within 7 days before the experimental drug for women of childbearing age.
排除标准
- •Participants with mild to moderate liver impairment who meet any of the following criteria will not be eligible for this study:
- •Subjects had any of the following conditions: drug-induced liver injury; history of liver transplantation; liver failure, or cirrhosis with grade 3/4 hepatic encephalopathy, esophageal and gastric varices bleeding and other complications considered inappropriate by researchers; severe / advanced peritoneal effusion or pleural effusion requiring puncture drainage and albumin supplement; patients with hepatorenal syndrome; patients with hepatorenal syndrome;
- •Biliary cirrhosis, biliary obstruction, cholestatic liver disease and other diseases that affect bile excretion;
- •Patients with severe portal hypertension or previous portosystemic shunt, including transjugular intrahepatic portosystemic shunt;
- •In addition to primary liver diseases, those who had previously suffered from serious primary diseases of other important organs were not suitable for the trial according to the judgment of the researchers;
- •Any of the following conditions occurred within 6 months prior to the study: Myocardial infarction, severe / unstable angina, symptomatic congestive heart failure (NYHA class II-IV), supraventricular or ventricular arrhythmias;
- •History of malignant tumor in the past 5 years;
- •Patients with severe infection, trauma, gastrointestinal surgery or other major surgical operations within 4 weeks before screening;
- •History of drug use, or have a history of drug abuse in the past five years, or have a positive drug screening (except those with drug screening positive due to concomitant drug use);
- •HIVAb positive, syphilisAb positive;
- •Pregnant or lactating women;
- •Strong inducers or inhibitors of CYP3A4, CYP2C9 or CYP2C8 were taken within 14 days before administration of the study drug; used traditional Chinese medicine, dietary supplements and vitamins;
- •Subjects with other factors not suitable to participate in this study were considered by the investigator.
研究组 & 干预措施
Healthy participants
Experimental
Intervention: Drug: SHR6390 single dose
干预措施: SHR6390 (Drug)
Mild liver impairment
Experimental
Intervention: Drug: SHR6390 single dose
干预措施: SHR6390 (Drug)
Moderate liver impairment
Experimental
Intervention: Drug: SHR6390 single dose
干预措施: SHR6390 (Drug)
结局指标
主要结局
Cmax
时间窗: Day1~Day9
Maximum concentration
AUC0-t
时间窗: Day1~Day9
Area under the concentration time curve from time zero to time t
AUC0-∞
时间窗: Day1~Day9
Area under the concentration time curve extrapolated to infinity
次要结局
未报告次要终点
研究者
相似试验
招募中
1 期
An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy ParticipantsHepatic ImpairmentHealthy ParticipantsNCT04631549Jiangsu HengRui Medicine Co., Ltd.24
已完成
1 期
A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired SubjectsHepatic ImpairmentNCT02857868Novartis Pharmaceuticals32
已完成
1 期
Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic ImpairmentHepatic ImpairmentNCT05599932Novartis Pharmaceuticals38
已完成
1 期
A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENTHepatic ImpairmentHealthy ParticipantsNCT04193436Pfizer23
已完成
1 期
A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver DysfunctionHepatic ImpairmentHealthy VolunteersNCT05478603Pfizer24